ConductScience.org, home
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
API referenceFor AI assistants

Trial · NCT03491215

Participant flow24

How many started, completed or left each group, period by period.

1 to 20 of 24

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDGroup 1: Subjects ≥ 12y to < 18y - RUX 10mg BID18
Overall StudySTARTEDGroup 2: Subjects ≥ 6y to < 12y - RUX 5mg BID12
Overall StudySTARTEDGroup 3: Subjects ≥ 2y to < 6y - RUX 4mg/m^2 BID15
Overall StudySTARTEDGroup 4: Subjects >= 28 Days to < 2y0
Overall StudyRux Formulation - Received TabletGroup 1: Subjects ≥ 12y to < 18y - RUX 10mg BID18
Overall StudyRux Formulation - Received TabletGroup 2: Subjects ≥ 6y to < 12y - RUX 5mg BID10
Overall StudyRux Formulation - Received TabletGroup 3: Subjects ≥ 2y to < 6y - RUX 4mg/m^2 BID0
Overall StudyRux Formulation - Received TabletGroup 4: Subjects >= 28 Days to < 2y0
Overall StudyRux Formulation - Received CapsuleGroup 1: Subjects ≥ 12y to < 18y - RUX 10mg BID0
Overall StudyRux Formulation - Received CapsuleGroup 2: Subjects ≥ 6y to < 12y - RUX 5mg BID2
Overall StudyRux Formulation - Received CapsuleGroup 3: Subjects ≥ 2y to < 6y - RUX 4mg/m^2 BID7
Overall StudyRux Formulation - Received CapsuleGroup 4: Subjects >= 28 Days to < 2y0
Overall StudyRux Formulation - Received Oral SolutionGroup 1: Subjects ≥ 12y to < 18y - RUX 10mg BID0
Overall StudyRux Formulation - Received Oral SolutionGroup 2: Subjects ≥ 6y to < 12y - RUX 5mg BID0
Overall StudyRux Formulation - Received Oral SolutionGroup 3: Subjects ≥ 2y to < 6y - RUX 4mg/m^2 BID8
Overall StudyRux Formulation - Received Oral SolutionGroup 4: Subjects >= 28 Days to < 2y0
Overall StudyCOMPLETEDGroup 1: Subjects ≥ 12y to < 18y - RUX 10mg BID11
Overall StudyCOMPLETEDGroup 2: Subjects ≥ 6y to < 12y - RUX 5mg BID10
Overall StudyCOMPLETEDGroup 3: Subjects ≥ 2y to < 6y - RUX 4mg/m^2 BID14
Overall StudyCOMPLETEDGroup 4: Subjects >= 28 Days to < 2y0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03491215/flow

API referenceFor AI assistants